MarketBeat
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight
📈
AI Sentiment
Highly Positive
9/10
Gilead Sciences Inc. News
Latest updates and market news for GILD
20 news
Feb 11 - Feb 17, 2026
Page 1
Simply Wall St.
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82
📈
AI Sentiment
Highly Positive
8/10
StockStory
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why
📈
AI Sentiment
Highly Positive
9/10
Zacks
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
âž–
AI Sentiment
Neutral
5/10
Zacks
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
📊
AI Sentiment
Positive
6/10
MT Newswires
Wolfe Adjusts Price Target on Gilead Sciences to $170 From $155, Maintains Outperform Rating
📊
AI Sentiment
Positive
7/10
Zacks
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case
📈
AI Sentiment
Highly Positive
9/10
Investor's Business Daily
Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says
📊
AI Sentiment
Positive
7/10
MT Newswires
Deutsche Bank Adjusts Gilead Sciences Price Target to $155 From $135, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
Pharmaceutical Technology
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Morgan Stanley Raises Price Target on Gilead Sciences to $171 From $150, Keeps Overweight Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Wells Fargo Adjusts Price Target on Gilead Sciences to $165 From $150, Maintains Overweight Rating
📈
AI Sentiment
Highly Positive
8/10
Share this news page